Why this call
Riding the Weight-Loss Wave
Extremely positive news flow from successful drug trials.
Strong underlying growth trend continues to attract investors.
Weather forecast
Eli Lilly and Co (LLY)
Sunny
Buy
Score 69/100 · Confidence 75%
The outlook is bright — conditions favour stepping in.
Weighed fromlive price action
Under the hood
What the engine weighed
Six factors, scored 0–100 from live market and financial data — the same read Wall Street does, minus the jargon.
0Overall score
Valuation
0
The stock appears expensive based on current earnings.
Growth
0
The company is posting exceptionally strong revenue growth.
Profitability
0
Lilly operates with very high and healthy profit margins.
Momentum
0
The stock has been in a powerful long-term uptrend.
Fin. health
0
The company carries a notable amount of debt.
Sentiment
0
Recent news has been overwhelmingly positive.
The argument
Both sides of the sky
Every call has a case against it. Here's the honest version of both.
The bull case
- Explosive revenue growth of nearly 50% driven by blockbuster drugs.
- Excellent profitability with a net margin over 33%.
- Strong positive news from successful clinical trials for new treatments.
The bear case
- High valuation with a P/E ratio of 41.6 suggests high expectations are already priced in.
- Significant debt load, with a Debt/Equity ratio of 1.62.
- The stock is trading near its 52-week high, which could make it vulnerable to pullbacks.
Get the full picture
That took thirty seconds.
Now imagine every stock you own.
You just understood LLY without reading a single chart. The Tickerday app does this for your whole watchlist — the full thesis, price targets from next week to next year, bull and bear scenarios — and wakes you the moment the weather turns.
One plain answer for every stock — Buy, Hold, or Sell
The full picture in seconds — thesis, targets & scenarios
Sleep easy — we watch the market and wake you if it turns
Free to download · 7-day free Tickerday+ trial inside